Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 16/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.39 |
| ▸ | DLK1 | P80370 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768061 | 1.00 | MAP3K12 (0.43) | MAP3K12PDE10AMAP3K13DLK1PRKDC | |
| SCHEMBL21997512 | 0.76 | MAP3K12 (0.40) | MAP3K12MAP3K13DLK1 | |
| SCHEMBL21997300 | 0.76 | MAP3K12 (0.40) | MAP3K12MAP3K13DLK1 | |
| SCHEMBL21996677 | 0.74 | IRAK4 (0.46) | — | |
| SCHEMBL25987203 | 0.74 | IRAK4 (0.46) | — | |
| SCHEMBL23945834 | 0.74 | IRAK4 (0.46) | — | |
| SCHEMBL21996976 | 0.74 | IRAK4 (0.46) | — | |
| SCHEMBL21997814 | 0.74 | IRAK4 (0.46) | — | |
| SCHEMBL30267251 | 0.74 | DYRK1A (0.33) | — | |
| SCHEMBL23807999 | 0.73 | NTRK1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368194-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-20230406866-A1 | CRYSTALLINE FORMS OF IRAK DEGRADERS | KYMERA THERAPEUTICS, INC. | 2023-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406866-A1 | CRYSTALLINE FORMS OF IRAK DEGRADERS | IRAK1, IRAK2, IRAK4 | MAP3K12 369/4885PDE10A 4064/4885MAP3K13 297/4885 |
| US-20240368194-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | MAP3K12 286/4885PDE10A 3347/4885MAP3K13 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.